Potent inhibitor of cyclin-dependent kinases (cdks) 9, 2 and 7 (IC50
values are 4, 38 and 62 nM respectively). Displays no activity against 190 additional kinases (IC50
>1000 nM). Arrests the cell cycle at G2
/M; inhibits transcription, proliferation and colony formation, and induces apoptosis in RPMI-8226 multiple myeloma cells. Prevents tumor cell-induced VEGF secretion and in vitro
Soluble to 50 mM in DMSO
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
Misra et al.
SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor.
Ali et al.
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Conroy et al.
Cancer Chemother.Pharmacol., 2009;64:723
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen et al.
Cancer Res., 2010;70:6587
The citations listed below are publications that use Tocris products. Selected citations for SNS 032 include:
Showing Results 1 - 1 of 1